Patent SG-11201805534T-A (SG)
Title: Formulation for antibody and drug conjugate thereof
Inventor: HARLOW LENE
IPC: A61K47/18
Filed: 2017-01-13
Abstract: 12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property -, Organization 1111111101111011101010111110101111101110111011101111101111111111101111011111 International Bureau 0.. .... .. ...... ... (10) International Publication Number International Publication Date WO 2017/121867 Al 20 July 2017 (20.07.2017) WIPO I PCT — (51) (21) (22) (25) Filing Language: (26) Publication Language: (30) (71) (72) Inventors: HARLOW, Lene, Schantz; C/O Genmab A/S, International Patent Classification: drew; 4517 Lazyriver Dr., Durham, NC 27712 (US). A61K 9/19 (2006.01) A61K 47/18 (2017.01) HALBLEIB, Cale; 208 Kings Castle Dr., Apex, NC A61K 9/00 (2006.01) A61K 47/26 (2006.01) 27502 (US). A61K 39/395 (2006.01) C07K 16/28 (2006.01) (74) Agent: GENMAB A/S; Bredgade 34 E, 1260 Copenhagen International Application Number: K (DK). PCT/EP2017/050700 (81) Designated States (unless otherwise indicated, for every International Filing Date: kind of national protection available): AE, AG, AL, AM, 13 January 2017 (13.01.2017) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, English BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, English HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, Priority Data: MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, 62/278,217 13 January 2016 (13.01.2016) US NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, Applicant: GENMAB A/S [DK/DK]; Bredgade 34 E, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, 1260 Copenhagen K (DK). TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. Bredgade 34 E, 1260 Copenhagen K (DK). PAUL, (84) Designated States (unless otherwise indicated, for every Timothy, Warren; 4102 W. Portage Trail, Bloomington, kind of regional protection available): ARIPO (BW, GH, IN 47404 (US). MAYHUGH, Brendan, M.; 7108 W. GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, Crown Circle, Bloomington, IN 47404 (US). ROBY, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, Kelly, Ann; 4356 W. McHaffey Woods Dr., Bloomington, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, IN 47403 (US). SACHA, Gregory, Allan; 4271 Whitetail DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, Woods Dr., Bargersville, IN 46106 (US). JING, Xiaona; LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, Burgstrasse 123, 4125 Riehen (CH). HAGARMAN, An- [Continued on next page] = - = = Title: FORMULATION FOR FIGURE 1 0,45 0,4 0,35 2 0,3 7 0,25 a) ma co 0 .. , 15 0, 0,05 : Disclosed herein are and ADCs, including aqueous and uses. The formulations are particularly suitable hydrophobic drugs. Some formulations comprise histidine and mannitol 0 similarly ANTIBODY AND DRUG SEC CONJUGATE THEREOF HMW Peaks = (54) = = = = — = = = = 04 F1 F3 F5 F7 F9 F11 F13 surfactant free antibody formulations, lyophilized formulations, 0 I Formulation F15 F17 and for an F19 F21 F23 F25 F27 F29 F31 F33 F35 designation antibody-drug anti-AXL ADC ®T=4 I t) , T=6 -conjugate (ADC) formulations for anti-AXL anti- and reconstituted formulations, as well as related pro - based on an auristatin or DM1 derivative or other = _ 11 .4 IN ,tD GC 11 ei Il IN 1-1 (57) = bodies \" cesses WO 2017/121867 Al 1#11101M011111 11111111ME30110111011101100ERVOIS SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, before the expiration of the time limit for amending the GW, KM, ML, MR, NE, SN, TD, TG). Published: claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) — with international search report (Art. 21(3)) — with sequence listing part of description (Rule 5.2(a))